# An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis

> **NCT02049138** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 493 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Upadacitinib
- **BIOLOGICAL:** Pneumococcal 13-valent conjugate vaccine (PCV-13)

## Key facts

- **NCT ID:** NCT02049138
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-24
- **Primary completion:** 2021-07-29
- **Final completion:** 2021-07-29
- **Target enrollment:** 493 (ACTUAL)
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02049138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02049138, "An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02049138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*